EP4 Antagonist

About Nxera Pharma

Nxera Pharma is a Tokyo-listed biopharma company that rebranded from Sosei Group in 2023 to reflect its evolution into a fully integrated R&D and commercial entity. Its core strategy is built on a GPCR-focused technology platform, strategic partnerships with major pharmaceutical companies, and a pipeline targeting high-need areas in CNS and immunology. The company aims to become a leading, innovation-driven biopharma player in the Asia-Pacific region and globally.

Therapeutic Areas